Concepedia

Rikke Holmgaard

RH

Statistics

Publications

20

Citations

3.2K

H-Index

18

Active since

2008

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Cornell University

Swim Across America

The University of Texas MD Anderson Cancer Center

Augusta University

Rikke Holmgaard is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cancer immunotherapy, and tumor immunology.

ORCID

Publications per year

2008–2021

20

Publications

20

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

Dmitriy Zamarin, Rikke Holmgaard, Sumit K. Subudhi et al. · Science Translational Medicine · 2014 · 704 citations

, , +17

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Rikke Holmgaard, Dmitriy Zamarin, David H. Munn et al. · The Journal of Experimental Medicine · 2013 · 636 citations · Full text

, , +17

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

Rikke Holmgaard, Dmitriy Zamarin, Yanyun Li et al. · Cell Reports · 2015 · 488 citations · Full text

, , +17

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 369 citations · Full text

, , +17

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 173 citations · Full text

, , +12

1–5 of 20